14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 8th May 2024 ARGX stock ended at $386.08. This is 3.19% less than the trading day before Tuesday, 7th May 2024. During the day the stock fluctuated 4.87% from a day low at $381.99 to a day high of $400.59.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical argenx SE prices

Date Open High Low Close Volume
May 08, 2024 $399.55 $400.59 $381.99 $386.08 277 428
May 07, 2024 $397.14 $398.81 $393.02 $398.81 203 710
May 06, 2024 $389.07 $397.35 $386.82 $393.78 203 220
May 03, 2024 $395.00 $397.18 $384.45 $388.20 139 374
May 02, 2024 $387.38 $393.69 $384.29 $393.42 199 165
May 01, 2024 $375.50 $390.87 $371.01 $383.34 228 706
Apr 30, 2024 $374.36 $377.06 $372.63 $375.50 110 962
Apr 29, 2024 $370.82 $379.34 $370.63 $375.29 132 029
Apr 26, 2024 $370.82 $375.59 $366.72 $372.80 228 781
Apr 25, 2024 $371.11 $377.78 $367.17 $368.60 279 900
Apr 24, 2024 $380.85 $380.85 $372.68 $375.00 202 220
Apr 23, 2024 $368.69 $377.94 $368.69 $375.08 340 247
Apr 22, 2024 $362.93 $370.80 $359.83 $368.75 318 551
Apr 19, 2024 $360.38 $362.50 $357.55 $360.23 322 389
Apr 18, 2024 $362.34 $367.49 $358.09 $358.41 235 021
Apr 17, 2024 $365.34 $367.53 $360.12 $366.20 267 474
Apr 16, 2024 $360.37 $375.47 $359.89 $370.68 201 738
Apr 15, 2024 $378.59 $386.49 $375.12 $376.26 189 280
Apr 12, 2024 $380.02 $381.77 $373.78 $378.02 133 063
Apr 11, 2024 $386.65 $387.62 $378.18 $379.65 93 342
Apr 10, 2024 $381.78 $385.33 $379.10 $382.78 130 731
Apr 09, 2024 $385.78 $389.49 $381.63 $384.14 216 827
Apr 08, 2024 $386.71 $388.38 $385.04 $386.71 99 422
Apr 05, 2024 $387.81 $388.97 $384.65 $387.03 119 409
Apr 04, 2024 $392.62 $395.82 $386.46 $386.88 144 193
Click to get the best stock tips daily for free!

About argenx SE

argenx SE argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid ... ARGX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT